Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GBL in the NBA

This article was originally published in The Tan Sheet

Executive Summary

The Phoenix Suns believe a product containing gamma butyrolactone caused forward Tom Gugliotta to suffer from seizures after a Dec. 17 game; the team is still looking at other possible causes of the seizures. Gugliotta reportedly took the product to help him sleep. Last January, FDA, which considers GBL an unapproved drug, requested a number of firms marketing products containing the compound to recall their stock; Congress also is considering legislation that would classify GBL as a controlled substance. The Gugliotta incident follows the recent suspension of Chicago Bears quarterback Jim Miller, who tested positive for a steroid he claimed was contained in a dietary supplement ("The Tan Sheet" Dec. 6, 1999, p. 12)
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS090719

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel